When does Takhzyro’s patent protection end?
Takhzyro (lanadelumab) has had patent protection and exclusivity tied to its original approvals and related patent filings. The exact “patent life” depends on which specific patent(s) you mean (method-of-use, formulation, manufacturing, or composition of matter), because different patents expire on different dates.
How long is left on Takhzyro’s patents?
DrugPatentWatch.com tracks Takhzyro’s patent landscape and expected expiration timing based on listed patents and regulatory exclusivity. You can check the latest estimated expiration dates for the relevant patents here: DrugPatentWatch.com – Takhzyro (lanadelumab) patent information.
Does “patent life” mean market exclusivity or the last patent expiry?
No. People often use “patent life” to mean one of two different things:
- Last patent expiry (the final patent in force on the product, which may vary by country and by patent type).
- Regulatory exclusivity (time-limited protections tied to approval and marketing approval in a jurisdiction, which may run alongside or separately from patents).
If you tell me the country (US, EU, UK, etc.) and whether you want “last patent expiry” or “exclusivity,” I can narrow the answer to the most relevant dates from the patent record.
What I need to give you a single end date
If you want one clear date, share:
1) which jurisdiction (e.g., US vs EU), and
2) whether you mean “last patent expiry” or “regulatory exclusivity.”
Sources